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To investigate the usefulness of thyroglobulin mRNA (Tg-mRNA) detection in peripheral blood in the follow-up of papillary and
follicular (differentiated) thyroid cancer, a literature study was performed. Both evidence for and evidence against the usefulness of
Tg-mRNA detection were found. Also, evidence for the expression of Tg-mRNA in cells other than normal or neoplastic thyroid
follicular cells was found. It is concluded that currently Tg-mRNA detection is not a useful tool in the follow-up of differentiated
thyroid carcinoma, but that the concept of using RT–PCR measurements during follow-up still warrants further research.
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Differentiated thyroid cancer is among the most manageable of
cancers; with a 10-year survival of 80–95% (Tubiana et al, 1985),
its prognosis is good. However, patients with differentiated thyroid
cancer can never be considered ‘cured’; recurrences do occur,
sometimes as late as 30 years after the original diagnosis (Tubiana
et al, 1985; Mazzaferi and Jhiang, 1994). It is therefore imperative
to regularly check these patients during a life-long follow-up.
Checking patients for the presence of persistent or recurrent
disease can be carried out by regular measurement of serum
thyroglobulin (Tg) levels, both during suppressed TSH and during
stimulation with high TSH levels, achieved either through
levothyroxine (LT4) withdrawal or administration of recombinant
human TSH, and periodic radioiodine whole-body scintigraphy
(WBS) after withdrawing LT4 supplementation.
However, both these methods do have drawbacks. It often
happens that I-131 WBS is negative, but serum Tg is readily
detectable (Pineda et al, 1995; Pachucki and Burmeister, 1997;
Fatourechi and Hay, 2000). One should remember that measure-
ment of Tg levels cannot be considered reliable if antibodies
against Tg are detected (Feldt-Rasmussen and Rasmussen, 1985;
Mariotti et al, 1995; Spencer and Wang, 1995).
The limitations of current techniques have prompted research
into new ways of detecting persistent or recurrent thyroid cancer.
One of these techniques is detection of circulating thyroid cells by
measurement of thyroglobulin messenger RNA (Tg-mRNA) in
peripheral blood, first reported by Ditkoff et al (1996). This
technique seems to be quite promising according to some authors
(Ditkoff et al, 1996; Ringel et al, 1998, 1999; Biscolla et al, 2000;
Savagner et al, 2002), but the results of other studies contradict its
usefulness (Bojunga et al, 2000; Bugalho et al, 2001; Bellantone
et al, 2001; Takano et al, 2001; ; Eszlinger et al, 2002; Span et al,
2003, Elisei et al, 2004).
The goal of this study is to review the pros and cons of Tg-
mRNA detection in peripheral blood and determine whether it can
currently be considered useful in the follow-up of differentiated
thyroid cancer.
THYROGLOBULIN mRNA
Thyroglobulin mRNA is a 8.7 kilobase (kb) transcript of the Tg
gene, which covers at least 300kb of DNA (Baas et al, 1986). It
codes for Tg, a 660 kilodalton (kDa) glycoprotein that serves as a
prohormone for thyroid hormone production.
With 2.6% of the total transcription products of thyrocytes, Tg-
mRNA is the most highly expressed mRNA transcript in normal
thyrocytes (Pauws et al, 2000). In neoplastic thyroid tissue,
however, its expression is considerably lower (Ohta et al, 1991;
Hoang-Vu et al, 1992; Lazar et al, 1999; Ringel et al, 2001).
TECHNIQUE OF DETECTION OF Tg-mRNA IN
PERIPHERAL BLOOD
After a blood sample is drawn from a patient, total RNA is
extracted from the sample, either directly from the blood or from
the mononuclear layer after separation by using commercially
available kits. The method varies only in details between the
studies reviewed here.
Subsequently, an aliquot, usually 1mg, of total RNA is reverse-
transcribed using various commercially available kits containing
viral reverse transcriptase (RT). The cDNA acquired from this
reaction is then amplified using a polymerase chain reaction
(PCR). Quantification of these reactions can be performed with
one of several methods.
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This can be carried out using a gel electrophoresis of the sample
with Tg-mRNA- negative and -positive controls, or by other
methods, based on detection of a specific sequence of RNA.
Sensitivity of assays can vary: Bojunga et al (2000) reported
using two different assays, one of which had a lower limit
of detection of 50–100 Tg-mRNA-producing cells per ml
blood and the other a lower limit of detection of 10–20
Tg-mRNA-producing cells per ml. Ringel et al report being
able to detect 10 Tg-mRNA-producing cells per ml (Ringel et al,
1998).
SIGNIFICANCE OF Tg-mRNA DETECTION IN
PERIPHERAL BLOOD
Investigation of the applicability of the RT–PCR reaction for the
detection of Tg-mRNA was based on the assumption that patients
with adequately treated thyroid cancer should not have circulating
Tg-mRNA-producing cells, nor should individuals without thyroid
cancer. Although the first studies showed promising results, later
reports pointed to some problems with this technique and were
sceptic concerning its usefulness.
Ditkoff et al (1996) first investigated the possibility of detecting
circulating malignant thyroid cells using an RT–PCR reaction for
the detection of Tg-mRNA; this could serve as an indicator of
postoperatively present metastatic thyroid cancer.
This investigation was based on the assumption that patients
with adequately treated thyroid cancer should not have circulating
Tg-mRNA-producing cells, nor should individuals without thyroid
cancer.
Pro
Ditkoff et al (1996) were the first to investigate the possibility of
detecting circulating malignant thyroid cells using RT–PCR. They
found that Tg-mRNA could be detected in all nine patients with
known metastatic thyroid cancer. Seven out of 78 patients with no
currently known metastases, of whom five had a history of
surgically treated metastases, also showed detectable Tg-mRNA in
peripheral blood samples. No Tg-mRNA was detected in six
patients with benign thyroid disorders or in seven healthy subjects.
The study of Ditkoff et al therefore clearly demonstrated the
usefulness of Tg-mRNA detection in the follow-up of thyroid
cancer patients by having positive cases and only negative
controls.
Two studies by Ringel et al (1998, 1999) showed that Tg-mRNA
detection could be useful in the follow-up of differentiated thyroid
cancer. In the first study, 33 patients had either thyroid bed uptake
(n¼19) or metastatic iodine-avid tissue (n¼14) on the most
recent withdrawal scan. In 12 out of 19 patients with thyroid
remnants on the most recent follow-up scintigram, Tg-mRNA
could be detected in their blood. In addition, all 14 patients with
metastatic disease showing on the most recent follow-up
scintigram had detectable Tg-mRNA in their peripheral blood.
Serum Tg levels were detectable in only 12 of these 33 patients.
Seven out of 35 patients with negative scintigrams were positive for
Tg-mRNA too. All 10 healthy control subjects turned out to be
positive for Tg-mRNA in peripheral blood due to the improved
sensitivity of the RT–PCR.
In the second study of Ringel et al, a quantitative method of Tg-
mRNA detection was used. Using a threshold of 3pgTgEqmg
 1
thyroid RNA for the detection of Tg-mRNA, analysis was positive
in 38% of patients with a negative follow-up scintigram, 75% of
patients with thyroid bed uptake, 84% of patients with cervical/
regional disease and 94% of patients with distant metastases.
Thyroglobulin antibodies were shown not to affect the result of the
analysis.
Contra
Bojunga et al (2000) reported that using a ‘normal sensitivity’
(30 cycles of PCR) resulted in the detection of Tg-mRNA in nine
out of 13 patients with thyroid cancer and known metastases,
63 out of 137 patients with a history of thyroid cancer without
known metastases, 21 out of 85 patients with benign thyroid
disorders and in nine out of 50 control subjects. Using a ‘high
sensitivity’ (40 cycles of PCR), however, resulted in the detection of
Tg-mRNA in peripheral blood of 11 out of 13 patients with thyroid
cancer and known metastases, 111 out of 137 patients with a
history of thyroid cancer without known metastases and also in
61 out of 85 patients with benign thyroid disorders and 41 out of
50 control subjects.
Takano et al (2001) reported in their study that Tg-mRNA could
be detected in samples from all patients who have had a
thyroidectomy. Additionally, no statistically significant difference
in expression levels could be found between patients with and
patients without metastases in a quantitative analysis.
Illegitimate transcription of Tg-mRNA
Tissue specificity of Tg gene expression by detection of Tg-mRNA
in various human tissues obtained through routine surgery was
investigated by Bojunga et al (2000). Using a ‘normal sensitivity’,
they found Tg-mRNA expression to be specific for thyroid tissue.
Using ‘high sensitivity’, on the other hand, resulted in the
detection of Tg-mRNA transcripts not only in thyroid tissue but
also in various other tissues.
This confirms the findings of Tallini et al (1998), who, when
studying 10 non-thyroid malignant human cell lines and 11 control
subjects (including one patient who had had a total laringectomy
for squamous cell carcinoma with a complete thyroidectomy),
found no detectable expression of Tg-mRNA after 30 cycles of
PCR, but found detectable Tg-mRNA expression in all samples
after 40 cycles of PCR.
On top of this, Bugalho et al (2001) reported in a study of
healthy individuals and patients who have had a thyroidectomy for
reasons other than thyroid cancer that expression of Tg-mRNA
was detectable in all subjects, and that quantitative analysis
revealed no significant difference between those with and those
without thyroid glands. Furthermore, they found that, when
separating the mononuclear and polymorphonuclear layer of the
blood samples for analysis, both layers showed expression of Tg-
mRNA, thereby suggesting that Tg-mRNA transcription also takes
place in circulating white blood cells.
The observations regarding the detection of Tg-mRNA in
patients and tissues where it should not be detected can be
attributed to a phenomenon called ‘illegitimate transcription’
(Chelly et al, 1989): any gene is expressed in any cell at very low,
but detectable, levels.
Filtering out illegitimate transcription
Savagner et al (2002) tried to circumvent this problem by using
prostate-specific antigen (PSA) mRNA to determine the level of
illegitimate transcription. Any patient expressing Tg-mRNA in
higher quantities than PSA-mRNA was expected to have circulat-
ing follicular thyroid cells. Thus, they tried to filter out the non-
thyroid expression of Tg-mRNA. Using this method, Savagner et al
found that serum Tg-mRNA detection has a better sensitivity for
detecting recurrent thyroid cancer than serum Tg measurement,
especially during LT4 suppression therapy. Instead of PSA,
Eszlinger et al (2002) and Span et al (2003) used beta-actin-
mRNA transcription levels for correcting the illegitimate tran-
scription. However, their results showed no statistical differences
between patients and controls with respect to corrected Tg-mRNA
expression levels.
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comparison of the different studies, a patient was considered to be
positive for the presence of thyroid (cancer) tissue if he/she had
proven thyroid cancer, and was showing either detectable serum
Tg levels or showed scintigraphic evidence for the presence of
disease when blood was drawn for Tg-mRNA detection.
DISCUSSION
The question we addressed here was whether Tg-mRNA detection
in peripheral blood can be used for follow-up in differentiated
thyroid cancer.
Thyroglobulin mRNA detection certainly does not turn out to be
specific for the presence of metastatic thyroid cancer: Tg-mRNA is
detected in peripheral blood samples of patients with benign
thyroid disorders and even in samples from healthy subjects
(Ringel et al, 1998; Tallini et al, 1998; Takano et al, 2001; Savagner
et al, 2002; Elisei et al, 2004). This suggests that Tg-mRNA-
producing cells are present in blood even in patients without
thyroid cancer, which could be attributed to illegitimate transcrip-
tion of Tg-mRNA, or could mean that cell shedding is a
physiologic rather than pathologic process, taking place even in
normal thyroids.
Especially remarkable is the finding of Bojunga et al that
changing the number of PCR cycles in analysis completely changes
the specificity of Tg-mRNA detection. This suggests that a
relatively low level of expression of Tg-mRNA transcription also
takes place in many other cells in the body, which, when
sufficiently enhanced, will also be detected when analysing with
PCR for the presence of circulating thyroid cells. This study
certainly provides compelling evidence for the occurrence of
illegitimate transcription of Tg-mRNA.
This hypothesis is certainly supported by the finding of Selliti
et al (2000), who reported that human kidney cells respond to TSH
stimulation with the production of Tg-mRNA. Additionally, when
using an immunofluorescent staining with a monoclonal anti-Tg
antibody, positive staining can be identified in the cytoplasm of
mesangial cells.
Possible enhancements to Tg-mRNA detection
Under the hypothesis that Tg-mRNA is expressed at low levels in
various human cell lines, and at higher levels in normal or
neoplastic thyroid cells, one could consider using a quantitative
RT–PCR reaction with a clearly defined threshold for detecting
Tg-mRNA. However, this might not be the solution. No significant
differences in expression levels between patients with thyroid
cancer and subjects without thyroid disorders or with benign
thyroid conditions could be detected by Takano et al (2001) and
Fenton et al (2001).
Determining the level of illegitimate transcription and correct-
ing for it, like Savagner et al, Eszlinger et al and Span et al did, is
also still open to further research: using PSA-mRNA should at least
be further validated. Accordingly, one can consider investigating
mRNA molecules other than PSA-mRNA or beta-actin-mRNA for
correction for illegitimate transcription.
Another option is to further experiment with varying sensitiv-
ities of the RT–PCR procedure: for example, 30 cycles of PCR
instead of 40 when using the same technique as Bojunga et al.
However, this option is also still open to research.
Ringel (2004) also suggested some interesting possibilities for
further research using RT–PCR in the follow-up of thyroid
carcinoma.
Alternatives to Tg-mRNA
As an alternative to the detection of Tg-mRNA, several groups
have investigated the possibility of using measurement of mRNA
of other thyroid-specific proteins in the follow-up of differentiated
thyroid carcinoma. Biscolla et al (2000) in their study also
investigated the possibility of detecting sodium–iodine symporter
(NIS) mRNA. Their results however showed no benefit from these
measurements: NIS-mRNA detection was inferior to Tg-mRNA
detection. Tallini et al (1998) in their study correlated the detection
of thyroid peroxidase (TPO) mRNA and Tg-mRNA. Thyroid
peroxidase mRNA was detected in the same samples of peripheral
blood as Tg-mRNA and was not found in samples in which Tg-
mRNA was lacking. Finally, Roddiger et al (2002) investigated the
use of TPO-mRNA exclusively. Thyroid peroxidase mRNA
expression in peripheral blood was detected in significantly
more number of patients with thyroid disease than in control
patients. It is also correlated with the presence of metastases, and
in patients without known metastases it is correlated significantly
with grade, lymph node stage at the time of diagnosis and Tg
levels. Based on these data, further investigation of TPO-mRNA
seems warranted.
Pauws et al (2000) have already analysed the entire spectrum of
transcripts from thyrocytes, using a method called ‘serial analysis
of gene expression’ (SAGE). More on this method can be found at
the URL www.sagenet.org. It should be analysed which of these
transcripts in the thyrocyte gene profile are unique to thyroid
epithelial cells. Any thyroid-specific mRNA transcript would also
be a candidate for use in follow-up. Perhaps the next step could
even be to analyse each patients’ thyroid carcinoma for its specific
gene profile and monitor the patient by detecting circulating cells
matching the profile at key points. Such key points would have to
be determined in future research.
Table 1 Summary of results of various studies into the usefulness of Tg-mRNA detection
Study Quantitative? False positive False negative True positive True negative Positive controls Negative controls
Ditkoff No 7/78 0/9 9/9 71/78 0/15 15/15
Biscolla No 3/19 5/14 10/15 16/19 — —
Ringel (1999) Yes 13/33 13/74 61/74 20/33 — —
Savagner Yes 3/15 6/25 19/25 12/15 — —
Bojunga, method 1 No 63/137 4/13 9/13 74/137 30/135 105/135
Bojunga, method 2 No 111/137 2/13 11/13 26/137 102/135 33/135
Elisei Yes 22/29 2/17 15/17 7/29 17/20 3/20
Takano Yes All patients and controls are positive
Bugalho Semi No difference in expression levels between individuals with and without thyroid glands
Bellantone No Varies according to histology
Eszlinger Yes No difference between patients with and without metastases or other thyroid diseases
Span Yes No difference between patients and controls
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The RT–PCR for Tg-mRNA has so far mainly been investigated for
use in the regular follow-up of all patients with differentiated
thyroid carcinoma, using only one measuring point. Even if Tg-
mRNA RT–PCR eventually does not turn out to be useful in the
regular follow-up of differentiated thyroid cancer, there might be
specific subsets of patients in whom this technique could be used.
In patients with medullar thyroid carcinoma, nonquantitative RT–
PCR for calcitonin mRNA turns out to correlate with the presence,
extent and aggressiveness of metastatic disease (Saller et al, 2002).
In this study by Saller et al, it was also found that in patients who
had a clinically significant response to chemotherapy, calcitonin
mRNA had become undetectable.
Perhaps RT–PCR for Tg-mRNA could be used in an analogous
way for the monitoring of response to therapy in patients with
known metastatic thyroid cancer, especially in those patients in
whom normal Tg measurements are not reliable due to the
presence of Tg antibodies. Especially, monitoring the progression
of Tg-mRNA expression levels over time might prove useful.
A single positive sample at any level might not be considered
irrefutable proof for the persistence or recurrence of disease, due
to phenomena such as illegitimate transcription, but a Tg-mRNA
level rising over time will reflect increasing activity of normal or
neoplastic thyrocytes. The RT–PCR analysis could possibly detect
recurring or persisting disease much earlier than Tg measurements
could, especially during LT4-suppressive therapy.
CONCLUSION
Based on the various studies reviewed in this paper, it can be
concluded that at this time there are still too many contradicting
results on the usefulness of Tg-mRNA detection in peripheral
blood; this technique can therefore not yet be considered a proven
and reliable method of following patients after treatment for
differentiated thyroid carcinoma.
Further research, for example, whether different levels
of sensitivity of arrays could produce a useful level of specificity,
or the usefulness of other thyroid-specific gene transcripts,
such as TPO-mRNA, should however be performed; further
thought should also be given to the use of complete gene
profiles of the tumour in the follow-up of differentiated thyroid
carcinoma.
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